- What changed in AIM news today?
- AIM ImmunoTech highlights DURIPANC trial testing Ampligen plus AstraZeneca’s Imfinzi in metastatic pancreatic cancer maintenance therapy: Final dosing has finished in the DURIPANC trial testing Ampligen with AstraZeneca’s Imfinzi after first-line chemotherapy for metastatic pancreatic cancer. Primary and secondary endpoint results have not been presented.
- Does Rallies summarize AIM news?
- Yes. Rallies summarizes AIM news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
- Is AIM research on Rallies investment advice?
- No. Rallies provides research, data, and educational context for AIM. It does not provide personalized investment advice.
